Yann Foricher
Head of Small Molecules Medicinal Chemistry Sanofi
Seminars
Thursday 12th November 2026
Panel Discussion: Target-Focused vs High-Throughput Approaches for Discovering Therapeutically Effective RNA-Targeting Small Molecules
9:00 am
- What are the advantages and challenges associated with target-focused approaches?
- What are the advantages and challenges associated with high-throughput phenotypic or cell-based functional screening approaches?
- How is phenotypic RNA modulation connected back to a specific RNA target, binding site, or mechanism of action?
- How does each approach manage generating actionable SAR and program attrition?
Thursday 12th November 2026
Panel Discussion: Establishing RNA-Targeted Small Molecules as a Generalizable Drug Modality
3:00 pm
- Which disease areas beyond rare genetic indications – respiratory, immunology, and other high-prevalence settings – are genuinely within reach, and what makes a target there tractable?
- What new chemotypes, mechanisms, and platforms are needed to expand beyond risdiplam- and branaplam-like analogs and a handful of target classes – and how far should we extend the one validated mechanism class versus seek genuinely new ones?
- What translational, safety, and selectivity evidence is required to convince the field that RNA targeting is a generalizable modality rather than a niche?